Cost Management for Global Drug Development Projects
Track
:
Track 02: Project/Portfolio Management and Strategic Planning
Program Code:
302
Date:
Wednesday, June 26, 2013
Time:
8:00 AM to 9:30 AM
EST
Location:
104C
CHAIR
:
Mark Kryah, (SCHNON), Advisor, Pharmaceutical Project Management, Eli Lilly and Company, United States
Mark Kryah has been leading projects from early to late phase development for over 16 years, with extensive international and cross-cultural experience. For the past 3 years, he has been responsible for global development of a portfolio of Lilly's Ph3/4 pipeline. Mr. Kryah has been a PMP since 1999.
SPEAKER
(S):
Mick O'Quigley, MBA (SPKNON), Program Group Leader, Genentech, A Member of the Roche Group, United States
Mick O'Quigley has over 20 years of drug development experience in the biopharmaceutical industry. Mick currently is a Program Group Leader in Clinical Operations at Genentech focusing on the development of early stage oncology molecules.
Carolyn O'Leary, MBA,PMP (SPKNON), Associate Director, Global Project Management, Merck & Co., Inc., United States
TBD
Frank P DePaoli, (SPKNON), Director, Pharmaceutical R&D Advisory Services, PricewaterhouseCoopers LLP, United States
Frank, a Director in PwC’s Pharma R&D Advisory practice, has 10+ years of experience leading projects aimed at optimizing R&D operations, processes, analytics & systems that support the planning, management & control of timelines, resources, costs, value & risk across pharma R&D project portfolios.
Description
What are the key aspects in developing and managing budgets for drug development projects? How are changes handled? These questions and others, as well as the role of the project manager in cost management, will be explored.